Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Digestive Diseases|July 13, 2022
Implementation of WeChat-based patient-doctor interaction in the management of Helicobacter pylori infection: A propensity score matching analysisBo Shen Lin, Yue Yue Li, Chen Qiao, et al.Journal of Gastroenterology and Hepatology|September 13, 2023
Efficacy and safety of a 14-day modified concomitant therapy for refractory Helicobacter pylori infection: a pilot studyShu-Yan Zeng, Juan Wang, Jing Liu, et al.Journal of Digestive Diseases|March 24, 2023
Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysisJuan Wang, Yue Yue Li, Min Juan Lin, et al.Journal of Digestive Diseases|July 26, 2022
Clinical practice of Helicobacter pylori infection management by gastroenterologists in secondary and tertiary hospitals: A stratified sampling cross-sectional surveyWen Lin Zhang, Yue Yue Li, Jing Liu, et al.Clinical and Experimental Medicine|December 20, 2022
The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysisYu-Ming Ding, Yue-Yue Li, Jing Liu, et al.Helicobacter|August 4, 2024
Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled TrialYu-Ming Ding, Qiu-Mei Zhang, Rui-Li Li, et al.Digestive Diseases and Sciences|May 3, 2024
Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial of 10 and 14 DaysYu-Ming Ding, Miao Duan, Zhong-Xue Han, et al.Helicobacter|April 24, 2025
Seven-Day Versus 14-Day Tegoprazan and Tetracycline-Containing Quadruple Therapy for First-Line Eradication of Helicobacter pylori Infection: A Randomized, Open-Label, Noninferiority TrialXue-Ping Nan, Hong-Yu Zhao, Lei-Na Guo, et al.Pageof 2